Aripiprazole Orally Disintegrating vs Brexpiprazole — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Atypical Antipsychotic

Aripiprazole Orally Disintegrating

Brand: Aripiprazole

First FDA approval: 2018-04-18

Atypical Antipsychotic

Brexpiprazole

Brand: Rexulti

First FDA approval: 2015-07-10

Lowest NADACAcquisition cost floor across all NDCs

$2.87Per unit

$49.50Per unit

Average NADACAcross all dosage forms and strengths

$3.30Up to $3.74

$49.60Up to $49.65

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

16 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

—Full year

$1.37BFull year

Part D claims (CY24)Total fills, all strengths

—— beneficiaries

972K179K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

—Per claim, all NDCs

$1,408Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

80Minimal friction

750Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

113Limited friction

42Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

NoBrand-only

Yes1 manufacturers